ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
about
DNA gyrase, topoisomerase IV, and the 4-quinolonesGene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysisGenetic diversity of the tet(M) gene in tetracycline-resistant clonal lineages of Streptococcus pneumoniae.Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistanceCharacterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in CanadaCloning and nucleotide sequence of the DNA gyrase gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant clinical isolatesPrevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genesAntibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococciContribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniaeHow antibiotics kill bacteria: from targets to networksParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE lociIn vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seFluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaeEfflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteriaLongitudinal assessment of antipneumococcal susceptibility in the United States.Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV.Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridgeNew alkaloid antibiotics that target the DNA topoisomerase I of Streptococcus pneumoniaeViridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniaeCharacterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniaeActive efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.First characterization of fluoroquinolone resistance in Streptococcus suis.Antibiotic resistances of starter and probiotic strains of lactic acid bacteria.Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
P2860
Q24643546-AB5DA00D-B80D-4099-90C3-14585ED94596Q28345923-9B1F6B95-74AE-408E-AC29-688508BF61D0Q33593820-715FEEA3-3E28-4438-AE7B-D35B98EB118DQ33594174-53A262E8-29A8-4F83-AB13-E26481ACCB57Q33595145-D344568B-F7C1-4CA4-B2EB-14C521418C09Q33663032-797D838E-E078-4D82-AA74-9288ED06DA7FQ33690745-DF1252F7-F8EB-44C6-9580-9F80DD662CA7Q33694946-1C2E25D0-088E-40E3-ACC7-F1C50EB047C7Q33695625-88859769-6D0C-41A7-9FC6-FC9EF5660989Q33696363-E2627AB6-D90B-44B9-B95D-140D29E30A14Q33700561-079D288A-3E09-4672-8C55-AA41D284A399Q33757558-E32C57D7-68EA-4327-998B-07EEC259FC9EQ33958766-EE564EB9-94F9-42F7-B35E-3D82A1F2800EQ33976037-CB536957-0CBF-4862-BFA6-A213EE16A029Q33976055-E8CE3D5B-0C0E-4218-95AC-75718186A80CQ33976279-1F308279-0B0B-491D-AB4E-EB8FF2632D64Q33978324-F7AF442E-5B06-43B2-8F06-D7A7AD3F82BDQ33978849-7A4CFE16-0019-4D02-8BB4-382F799F4545Q33980313-062F20CE-57D8-49DC-9A40-890239C426BAQ33980574-61F71063-29E4-4DB5-9A27-373A244925A6Q33980689-F6244DCB-2918-4CCA-B6B3-258FB124402AQ33980747-A7A6ED15-0126-4F21-82C8-8FD63C1DF65DQ33981343-E444EBA4-73DD-4136-B077-B5A9B1B32845Q33981750-5F4E99DC-DE5E-4555-A10F-5BAA7E37DEC6Q33983643-AA68D947-77FA-4310-AEB8-0CAF6E16AEA1Q34035762-E472A81E-2EB6-4721-8FF1-4049DE9A0C8CQ34110932-4D27ECB2-F8B1-4136-A7A2-87D0CDEE16B6Q34113933-4C44EF44-478F-4010-A36B-3153E02FB14AQ34119765-1BA2F91E-32F6-467F-B434-BBD3A983D440Q34301541-81F6F1BC-8B69-4629-A4FB-7CD7254D903BQ34597404-555D2ECB-99E0-40CE-A7C2-4782E8801A91Q34675643-89105ED9-1BB8-4B6C-8B56-FEF908B11727Q35102420-65CE154A-53CE-48BB-B6E5-38D7A6F53218Q35136293-C82E5BAC-C4AE-433E-8BAD-530758E33B75Q35138154-B5F32640-E7E7-4C7C-81E6-5D3962344218Q35139545-3B520BAE-C830-46EB-BC2C-FBBCA5E31B1CQ35140423-AC80A8C0-A414-46C4-A728-BDD69FCA3397Q35636018-540C390D-564F-472A-A59C-56A0CBF0B7CEQ35642002-F5442B1F-BB36-42F5-8A08-7FB18AEFA32FQ35682250-DBB5F3F7-010D-47B9-B8E9-176B323427D8
P2860
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
ParC subunit of DNA topoisomer ...... forming resistance phenotype.
@en
ParC subunit of DNA topoisomer ...... forming resistance phenotype.
@nl
type
label
ParC subunit of DNA topoisomer ...... forming resistance phenotype.
@en
ParC subunit of DNA topoisomer ...... forming resistance phenotype.
@nl
prefLabel
ParC subunit of DNA topoisomer ...... forming resistance phenotype.
@en
ParC subunit of DNA topoisomer ...... forming resistance phenotype.
@nl
P2860
P1476
ParC subunit of DNA topoisomer ...... forming resistance phenotype.
@en
P2093
De La Campa AG
P2860
P304
P407
P577
1996-10-01T00:00:00Z